Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK 831 in Healthy Adult Asian Subjects

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK 831 in Healthy Adult Asian Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs TAK 831 (Primary)
  • Indications Ataxia; Friedreich's ataxia; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 05 Nov 2018 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
    • 30 Oct 2018 Planned number of patients changed from 32 to 40.
    • 30 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top